Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | CASP3 | Direct | 1 | ||||||||
| minocycline, placebo, questionnaires | CASP3 | Direct | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | CASP3 | Direct | 1 | ||||||||
| afatinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| dacomitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| erlotinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| gefitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| lazertinib and amivantamab | EGFR | SSL via EGFR | 1 | ||||||||
| osimertinib | EGFR | SSL via EGFR | yes | 1 | |||||||
| sunitinib | PDGFRB | SSL via PDGFRB | yes | 5 | |||||||
| docetaxel, thalidomide | BCL2 | SSL via BCL2 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | BCL2 | SSL via BCL2 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | NTRK1 | SSL via NTRK1 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | PDGFRB | SSL via PDGFRB | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | RAF1 | SSL via RAF1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | NTRK1 | SSL via NTRK1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | PDGFRB | SSL via PDGFRB | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | RAF1 | SSL via RAF1 | 4 | ||||||||
| ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine | TYMS | SSL via TYMS | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT1 | SSL via AKT1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | LYN | SSL via LYN | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | NTRK1 | SSL via NTRK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PDGFRB | SSL via PDGFRB | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | RAF1 | SSL via RAF1 | 3 | ||||||||
| amg 193, docetaxel, comparator amg 193 test tablet | BCL2 | SSL via BCL2 | 3 | ||||||||
| bms-986340, bms-936558-01, docetaxel | BCL2 | SSL via BCL2 | 3 | ||||||||
| capecitabine, cisplatin | TYMS | SSL via TYMS | 3 | ||||||||
| gemcitabine | TYMS | SSL via TYMS | 3 | ||||||||
| srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab | TYMS | SSL via TYMS | 3 | ||||||||
| 5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin | TYMS | SSL via TYMS | 2 | ||||||||
| ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin | TYMS | SSL via TYMS | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | RAF1 | SSL via RAF1 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | TYMS | SSL via TYMS | 2 | ||||||||
| alvocidib, paclitaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| alvocidib, paclitaxel | CDK1 | SSL via CDK1 | 2 | ||||||||
| alvocidib, paclitaxel | CDK5 | SSL via CDK5 | 2 | ||||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | BCL2 | SSL via BCL2 | 2 | ||||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | TYMS | SSL via TYMS | 2 | ||||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | TYMS | SSL via TYMS | 2 | ||||||||
| avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 | TYMS | SSL via TYMS | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | LYN | SSL via LYN | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | PDGFRB | SSL via PDGFRB | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | TYMS | SSL via TYMS | 2 | ||||||||
| bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis | TYMS | SSL via TYMS | 2 | ||||||||
| biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging | TYMS | SSL via TYMS | 2 | ||||||||
| biospecimen collection, computed tomography, pemetrexed | TYMS | SSL via TYMS | 2 | ||||||||
| bryostatin 1, paclitaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| bryostatin 1, paclitaxel | CASP8 | SSL via CASP8 | 2 | ||||||||
| bryostatin 1, paclitaxel | CCND1 | SSL via CCND1 | 2 | ||||||||
| btla inhibitor (js004), toripalimab, paclitaxel, cisplatin | BCL2 | SSL via BCL2 | 2 | ||||||||
| capecitabine | TYMS | SSL via TYMS | yes | 2 | |||||||
| capecitabine, carboplatin, epirubicin hydrochloride | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, docetaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| capecitabine, docetaxel | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, irinotecan hydrochloride | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, oxaliplatin | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, temozolomide | TYMS | SSL via TYMS | 2 | ||||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, docetaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| carboplatin, paclitaxel, panitumumab, radiotherapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, paclitaxel, three-dimensional conformal radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cetuximab, cisplatin, fluorouracil, conventional surgery | TYMS | SSL via TYMS | 2 | ||||||||
| chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy | TYMS | SSL via TYMS | 2 | ||||||||
| chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, surgical procedure, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, paclitaxel, surgical procedure, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab | TYMS | SSL via TYMS | 2 | ||||||||
| cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study | BCL2 | SSL via BCL2 | 2 | ||||||||
| dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg | BCL2 | SSL via BCL2 | 2 | ||||||||
| docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone | BCL2 | SSL via BCL2 | 2 | ||||||||
| durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel | TYMS | SSL via TYMS | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | JAK2 | SSL via JAK2 | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | NTRK1 | SSL via NTRK1 | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | PDGFRB | SSL via PDGFRB | 2 | ||||||||
| erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 | TYMS | SSL via TYMS | 2 | ||||||||
| filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| filgrastim, paclitaxel, topotecan hydrochloride | BCL2 | SSL via BCL2 | 2 | ||||||||
| filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, gemcitabine hydrochloride, leucovorin calcium | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, oxaliplatin, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 |